Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Amortization - Intangibles (2019 - 2024)

Akebia Therapeutics (AKBA) has disclosed Amortization - Intangibles for 6 consecutive years, with $9.0 million as the latest value for Q4 2024.

  • Quarterly Amortization - Intangibles changed 0.0% to $9.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Sep 2025, down 75.0% year-over-year, with the annual reading at $36.0 million for FY2024, 0.0% changed from the prior year.
  • Amortization - Intangibles for Q4 2024 was $9.0 million at Akebia Therapeutics, roughly flat from $9.0 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $9.1 million in Q2 2020, with the low at $6.1 million in Q3 2020.
  • Average Amortization - Intangibles over 5 years is $8.8 million, with a median of $9.0 million recorded in 2021.
  • The sharpest move saw Amortization - Intangibles tumbled 32.91% in 2020, then surged 47.58% in 2021.
  • Over 5 years, Amortization - Intangibles stood at $8.3 million in 2020, then rose by 8.42% to $9.0 million in 2021, then changed by 0.0% to $9.0 million in 2022, then changed by 0.0% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $9.0 million, $9.0 million, and $9.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.